Regulus Therapeutics has signed a new collaboration agreement with Biogen Idec to identify microRNA biomarkers in multiple sclerosis (MS).

The research will be carried out at the Regulus microMarkers division and will focus on profiling whole blood samples of patients treated with a Biogen MS therapy to identify microRNA signatures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the new agreement, Regulus will receive $2m upfront and is eligible for future payments upon reaching certain milestones related to the identification of potential microRNA signatures.

In August 2012, the firms teamed up and profiled more than 400 serum samples from MS patients, comparing them with the profiles of healthy volunteers.

"Our collaboration has made significant progress to date and we are hopeful to continue to help advance Biogen Idec’s leading multiple sclerosis franchise in a meaningful way with our innovative technology platform."

Regulus has used its reproducible and proprietary technology platform to extract, profile, and analyse microRNAs from small volumes of blood such as plasma, serum or whole blood.

The results from these experiments have enabled the companies to expand the scope of their research under the new agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Regulus Therapeutics chief business officer and general counsel David Szekeres said: "We are pleased to grow the Regulus microMarkers division and expand our research on microRNA biomarkers with Biogen Idec.

"Our collaboration has made significant progress to date and we are hopeful to continue to help advance Biogen Idec’s leading multiple sclerosis franchise in a meaningful way with our innovative technology platform."

MicroRNAs are small RNA molecules with around 20 to 25 nucleotides in length. They regulate gene expression rather than encoding proteins.